LICENSE REVENUE (Tables)

12 Months Ended

Dec. 31, 2024

Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]

Schedule of License and Grant Revenue

The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands):

	YEAR ENDED DECEMBER 31,
	2024		2023
License fee revenue
Regeneron Pharmaceuticals, Inc.	$	200	$	—
Phylaxis BioScience, LLC	—		1,634
Other	—		166
Total license fee revenue	$	200	$	1,800